13F Holdings
中文EN

ASMB ASSEMBLY BIOSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1426800 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY80.2%
TTM net income YoY71.2%
TTM EPS YoY116.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-31.8%
Net margin-16.6%
FCF margin-60.7%
EBITDA margin-31.7%

Returns

ROE-4.6%
ROA-3.9%
ROIC (approx.)-7.8%
Asset turnover0.24x

Leverage & solvency

Liabilities / assets8.1%
Debt / equity0.00x
Current ratio12.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.65x
Accruals ratio10.4%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$72.30M$28.52M$7.16M$0$6.25M
R&D expense$64.81M$55.93M$48.90M$69.98M$68.52M
SG&A expense$19.61M$18.01M$22.91M$24.13M$28.78M
Operating income-$12.12M-$45.42M-$64.65M-$94.11M-$132.69M
Pretax income-$6.12M-$39.85M-$61.20M-$93.09M-$132.39M
Income tax$0$330,000$33,000$0-$2.53M
Net income-$6.12M-$40.18M-$61.23M-$93.09M-$129.85M
EBITDA-$11.99M-$45.29M-$64.20M-$93.62M-$132.22M
EPS (basic)-0.55-6.69-13.38-23.08-3.00
EPS (diluted)-0.55-6.69-13.38-23.08-3.00
Weighted avg. shares (diluted)11.21M6.00M4.58M4.03M43.28M
Balance sheet
Cash & equivalents$58.45M$38.34M$19.84M$52.42M$45.63M
Short-term investments$189.66M$73.73M$110.41M$39.19M$101.00M
Receivables$974,000$0$43,000$944,000$336,000
Current assets$254.55M$115.50M$133.79M$96.97M$154.20M
PP&E, net$221,000$284,000$385,000$743,000$1.14M
Total assets$257.59M$119.17M$136.82M$101.79M$191.06M
Current liabilities$48.78M$47.80M$39.23M$16.30M$16.07M
Total liabilities$50.84M$85.81M$95.73M$19.13M$22.13M
Shareholders' equity$206.75M$33.36M$41.10M$82.66M$168.93M
Shares outstanding15.86M7.46M5.48M4.07M48.12M
Cash flow statement
Operating cash flow-$41.09M-$51.12M$22.74M-$84.46M-$93.40M
Capital expenditure$66,000$28,000$255,000$102,000$3.10M
Free cash flow-$41.16M-$51.15M$22.49M-$84.56M-$96.49M
Investing cash flow-$113.47M$40.17M-$69.14M$90.64M$26.52M
Financing cash flow$174.67M$29.45M$13.82M$614,000$53.06M
Depreciation & amortization$129,000$129,000$450,000$498,000$466,000
Stock-based compensation$4.68M$3.12M$5.12M$6.59M$5.24M

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.